Abstract
AimCetuximab is a standard-of-care treatment for KRAS wild-type metastatic colorectal cancer (mCRC), but it may also be effective in a subgroup of KRAS mutant patients by its immunomodulatory activity. Here,...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have